Bris­tol My­ers Squibb catch­es the SHP2 wave in a new col­lab­o­ra­tion deal with Bridge­Bio

Once con­sid­ered “un­drug­gable,” the phos­phatase en­zyme SHP2 has seen re­cent in­ter­est from a suite of Big Phar­mas, in­clud­ing As­traZeneca, Am­gen, No­var­tis and Mer­ck. Now Bris­tol …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER